TP53 and endometrioid adenocarcinoma: Concerning the 81 low-grade endometrioid cancers in our series, 9.88% were p53-mutated; of the 12 high-grade endometrioid carcinomas, 33.33% were p53-mutated; of the 17 serous cancers, 88.24% were mutated; of the 3 clear cell cancers, 66% were mutated; and of the 3 carcinosarcomas, 100% were mutated (Table 5).